Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Cost burden of diffuse large B-cell lymphoma.

Harkins RA, Patel SP, Flowers CR.

Expert Rev Pharmacoecon Outcomes Res. 2019 Oct 22:1-17. doi: 10.1080/14737167.2019.1680288. [Epub ahead of print]

PMID:
31623476
2.

Influence of eyelid pigmentation on the diagnosis of meibomian gland dysfunction.

Blumberg MJ, Millen AE, Patel SP.

Clin Ophthalmol. 2019 Sep 19;13:1815-1821. doi: 10.2147/OPTH.S222451. eCollection 2019.

3.

Management of Paraesophageal Hernia in the Morbidly Obese Patient.

Bakhos CT, Patel SP, Petrov RV, Abbas AE.

Thorac Surg Clin. 2019 Nov;29(4):379-386. doi: 10.1016/j.thorsurg.2019.07.003. Epub 2019 Sep 26. Review.

PMID:
31564394
4.

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):e31-e43. doi: 10.1164/rccm.201906-1202ST.

PMID:
31518182
5.

Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein JS, Merdan S, Flowers CR, Koff JL.

Expert Rev Hematol. 2019 Sep 12:1-15. doi: 10.1080/17474086.2019.1660159. [Epub ahead of print]

PMID:
31513757
6.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.

J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665-3. doi: 10.1016/j.jtho.2019.08.003. [Epub ahead of print]

PMID:
31446141
7.

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.

Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN Jr, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH.

Clin Cancer Res. 2019 Aug 16. doi: 10.1158/1078-0432.CCR-19-0578. [Epub ahead of print]

PMID:
31420359
8.

Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.

Mahdavi Fard A, Pourafkari L, Patel SP, Nader ND.

Ther Adv Chronic Dis. 2019 Aug 1;10:2040622319865657. doi: 10.1177/2040622319865657. eCollection 2019. No abstract available.

9.

Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.

Schvartsman G, Ma J, Bassett RL Jr, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC.

Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454. [Epub ahead of print]

PMID:
31398264
10.

Proposing a stratification scheme for Chronic Pruritus of Unknown Origin Nomenclature based on presence of eosinophilia: Implications for therapeutics and cohort homogeneity for clinical trials.

Patel SP, Khanna R, Kwatra SG.

J Am Acad Dermatol. 2019 Jul 29. pii: S0190-9622(19)32474-0. doi: 10.1016/j.jaad.2019.07.081. [Epub ahead of print] No abstract available.

PMID:
31369768
11.

Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Am J Clin Oncol. 2019 Sep;42(9):711-716. doi: 10.1097/COC.0000000000000577.

PMID:
31335350
12.

Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents.

Patel DV, Patel NR, Kanhed AM, Patel SP, Sinha A, Kansara DD, Mecwan AR, Patel SB, Upadhyay PN, Patel KB, Shah DB, Prajapati NK, Murumkar PR, Patel KV, Yadav MR.

ACS Chem Neurosci. 2019 Aug 21;10(8):3635-3661. doi: 10.1021/acschemneuro.9b00226. Epub 2019 Jul 29.

PMID:
31310717
13.

Elevated Blood Cadmium and Lead Levels in Chronic Pruritic Dermatoses.

Patel SP, Khanna R, Belzberg M, Kang S, Kwatra SG.

J Invest Dermatol. 2019 Jun 26. pii: S0022-202X(19)31797-X. doi: 10.1016/j.jid.2019.06.130. [Epub ahead of print] No abstract available.

PMID:
31254516
14.

Fractional CO2 Laser Treatment Outcomes for Pediatric Hypertrophic Burn Scars.

Patel SP, Nguyen HV, Mannschreck D, Redett RJ, Puttgen KB, Stewart FD.

J Burn Care Res. 2019 Jun 21;40(4):386-391. doi: 10.1093/jbcr/irz046.

PMID:
31225898
15.

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale.

Tyan A, Patel SP, Block S, Hughes T, McCowen KC.

Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):235-237. doi: 10.1016/j.mayocpiqo.2019.02.003. eCollection 2019 Jun.

16.

Mechanisms of voice control related to prosody in autism spectrum disorder and first-degree relatives.

Patel SP, Kim JH, Larson CR, Losh M.

Autism Res. 2019 Aug;12(8):1192-1210. doi: 10.1002/aur.2156. Epub 2019 Jun 12.

17.

Voluntary exercise may activate components of pro-survival risk pathway in the rat heart and potentially modify cell proliferation in the myocardium.

Lonek L, Puhova A, Griecsova-Kindernay L, Patel SP, Zohdi V, Jezova D, Ravingerova T.

Physiol Res. 2019 Aug 29;68(4):581-588. Epub 2019 Jun 6.

18.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 May 31. pii: mdz176. doi: 10.1093/annonc/mdz176. [Epub ahead of print]

PMID:
31150059
19.

Effect of Heavy Mass Ion (Gold) and Light Mass Ion (Boron) Irradiation on Microstructure of Tungsten.

Sharma P, Maya P, Akkireddy S, Raole PM, Tyagi AK, Attri A, Kulriya PK, Bajpai PK, Mishra S, Patel SP, Trivedi T, Khan KB, Deshpande SP.

Microsc Microanal. 2019 May 28:1-7. doi: 10.1017/S1431927619000667. [Epub ahead of print]

PMID:
31134875
20.

GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma.

Bordin-Wosk T, Patel SP, Horman SF.

J Gen Intern Med. 2019 Aug;34(8):1658-1661. doi: 10.1007/s11606-019-05040-4. Epub 2019 May 6.

PMID:
31062226
21.

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.

22.

Extrarenal Signs of Proximal Renal Tubular Acidosis Persist in Nonacidemic Nbce1b/c-Null Mice.

Salerno EE, Patel SP, Marshall A, Marshall J, Alsufayan T, Mballo CSA, Quade BN, Parker MD.

J Am Soc Nephrol. 2019 Jun;30(6):979-989. doi: 10.1681/ASN.2018050545. Epub 2019 Apr 30.

PMID:
31040187
23.

Cholestatic pruritus: Emerging mechanisms and therapeutics.

Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG.

J Am Acad Dermatol. 2019 Apr 19. pii: S0190-9622(19)30627-9. doi: 10.1016/j.jaad.2019.04.035. [Epub ahead of print] Review.

PMID:
31009666
24.

Improving Estimates of Annual Survival Rates for Medial Unicompartmental Knee Arthroplasty, a Meta-Analysis.

Heaps BM, Blevins JL, Chiu YF, Konopka JF, Patel SP, McLawhorn AS.

J Arthroplasty. 2019 Jul;34(7):1538-1545. doi: 10.1016/j.arth.2019.02.061. Epub 2019 Mar 6. Review.

PMID:
30954408
25.

Oral guaifenesin for treatment of filamentary keratitis: A pilot study.

Coco G, Amparo F, Patel SP, Foulsham W, Carreno-Galeano JT, Stockslager SG, Ciolino JB, Yin J, Dana R.

Ocul Surf. 2019 Jul;17(3):565-570. doi: 10.1016/j.jtos.2019.03.008. Epub 2019 Apr 1.

PMID:
30946892
26.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
27.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

28.

Effects of amantadine on corneal endothelium.

Dudley CE, Morell AJ, Duffey ME, Patel SP.

Exp Eye Res. 2019 Apr;181:208-212. doi: 10.1016/j.exer.2019.02.010. Epub 2019 Feb 13.

PMID:
30771294
29.

Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.

Mahdavi Fard A, Patel SP, Pourafkari L, Nader ND.

Ther Adv Chronic Dis. 2019 Jan 31;10:2040622318820850. doi: 10.1177/2040622318820850. eCollection 2019.

30.

Adjuvant Ipilimumab in High-Risk Uveal Melanoma.

Fountain E, Bassett RL, Cain S, Posada L, Gombos DS, Hwu P, Bedikian A, Patel SP.

Cancers (Basel). 2019 Jan 29;11(2). pii: E152. doi: 10.3390/cancers11020152.

31.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

32.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Apr 1;5(4):529-536. doi: 10.1001/jamaoncol.2018.5904.

PMID:
30605213
33.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
34.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
35.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
36.

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW, Hwu P, Hwu WJ, Patel SP, Liu M, Kim KB.

Cancer Epidemiol. 2018 Dec;57:80-84. doi: 10.1016/j.canep.2018.10.003. Epub 2018 Oct 19.

PMID:
30347335
37.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

38.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P.

J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x.

39.

Effects of taurine acute intake on cortical excitability and post-exercise facilitation: A TMS study.

Infortuna C, Milisits TF, Shaju S, Desai JK, Patel SP, Sheikh AM, Chusid E, Han Z, Battaglia F.

Behav Brain Res. 2019 Feb 1;359:719-722. doi: 10.1016/j.bbr.2018.09.014. Epub 2018 Sep 21.

PMID:
30248365
40.

Emergency Laparotomy in the Critically Ill: Futility at the Bedside.

Martin ND, Patel SP, Chreiman K, Pascual JL, Braslow B, Reilly PM, Kaplan LJ.

Crit Care Res Pract. 2018 Aug 26;2018:6398917. doi: 10.1155/2018/6398917. eCollection 2018.

41.

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy.

Li Y, Patel SP, Roszik J, Qin Y.

Front Immunol. 2018 Jul 16;9:1591. doi: 10.3389/fimmu.2018.01591. eCollection 2018. Review.

42.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.

PMID:
30006423
43.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571
44.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

45.

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.

Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP.

Oncologist. 2018 Oct;23(10):1236-1241. doi: 10.1634/theoncologist.2017-0375. Epub 2018 May 16.

46.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C.

J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230.

PMID:
29757889
47.

Leptomeningeal disease in uveal melanoma: a case series.

Glitza IC, Reddy ST, Patel SP.

J Neurooncol. 2018 Sep;139(2):503-505. doi: 10.1007/s11060-018-2878-5. Epub 2018 Apr 27. No abstract available.

PMID:
29704079
48.

Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies.

Wiesenthal AC, Patel SP, LeBlanc TW, Roeland EJ, Kamal AH.

J Palliat Med. 2018 May;21(5):694-699. doi: 10.1089/jpm.2018.0107. Epub 2018 Apr 16.

PMID:
29658821
49.

Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury.

Gollihue JL, Patel SP, Eldahan KC, Cox DH, Donahue RR, Taylor BK, Sullivan PG, Rabchevsky AG.

J Neurotrauma. 2018 Aug 1;35(15):1800-1818. doi: 10.1089/neu.2017.5605. Epub 2018 Apr 30.

50.

Obstacles to improving outcomes in the treatment of uveal melanoma.

Tsai KK, Bollin KB, Patel SP.

Cancer. 2018 Jul 1;124(13):2693-2703. doi: 10.1002/cncr.31284. Epub 2018 Mar 26. Review.

Supplemental Content

Loading ...
Support Center